{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:46:17Z","timestamp":1762911977201,"version":"3.45.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["FD-R-1983-01"],"award-info":[{"award-number":["FD-R-1983-01"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009210","name":"Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["archives-rrct.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Rehabilitation Research and Clinical Translation"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.arrct.2021.100123","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T02:10:54Z","timestamp":1617847854000},"page":"100123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase IIB Randomized Trial on the Use of 4-Aminopyridine in Guillain-Barr\u00e9 Syndrome"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4078-2436","authenticated-orcid":false,"given":"Jay M.","family":"Meythaler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Peduzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arrct.2021.100123_bib0001","series-title":"Spinal cord injury medicine","first-page":"584","article-title":"Acute and chronic inflammatory demyelinating polyneuropathies","author":"Meythaler","year":"2018"},{"key":"10.1016\/j.arrct.2021.100123_bib0002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.arrct.2021.100123_bib0003","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.mayocp.2016.12.002","article-title":"Guillain-Barre syndrome","volume":"92","author":"Wijdicks","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.arrct.2021.100123_bib0004","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barre syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.arrct.2021.100123_bib0005","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/archneur.62.8.1194","article-title":"Supportive care for patients with Guillain-Barre syndrome","volume":"62","author":"Hughes","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.arrct.2021.100123_bib0006","doi-asserted-by":"crossref","first-page":"15964","DOI":"10.1016\/0304-3959(94)90068-X","article-title":"Pain in the Guillain-Barr\u00e9 syndrome: a clinical review","volume":"59","author":"Pentland","year":"1994","journal-title":"Pain"},{"key":"10.1016\/j.arrct.2021.100123_bib0007","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.61.6.736","article-title":"Practice parameter: immunotherapy for Guillain-Barr\u00e9 syndrome. Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"61","author":"Hughes","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.arrct.2021.100123_bib0008","article-title":"Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barr\u00e9 syndrome","volume":"1","author":"Doets","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arrct.2021.100123_bib0009","doi-asserted-by":"crossref","first-page":"10319","DOI":"10.1089\/neu.1991.8.103","article-title":"The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial","volume":"8","author":"Blight","year":"1991","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.arrct.2021.100123_bib0010","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1089\/neu.1993.10.19","article-title":"Aminopyridines and the treatment of spinal cord injury","volume":"10","author":"Waxman","year":"1993","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.arrct.2021.100123_bib0011","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1001\/archneur.1994.00540150090022","article-title":"4-Aminopyridine in the treatment of patients with multiplesclerosis. Long-term efficacy and safety","volume":"51","author":"Polman","year":"1994","journal-title":"Arch Neurol"},{"key":"10.1016\/j.arrct.2021.100123_bib0012","doi-asserted-by":"crossref","first-page":"12330","DOI":"10.1002\/ana.410320203","article-title":"The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study","volume":"32","author":"van Diemen","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/j.arrct.2021.100123_bib0013","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1212\/WNL.54.3.603","article-title":"A randomized trial of 3,4diaminopyridine in Lambert-Eaton myasthenic syndrome","volume":"54","author":"Sanders","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.arrct.2021.100123_bib0014","first-page":"7787","article-title":"Regenerating mammalian nerve fibres: changes in action potential waveform and firing characteristics following blockage of potassium conductance","volume":"217","author":"Kocsis","year":"1982","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"10.1016\/j.arrct.2021.100123_bib0015","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1038\/304640a0","article-title":"Long-term regenerated nerve fibres retain sensitivity to potassium channel blocking agents","volume":"304","author":"Kocsis","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.arrct.2021.100123_bib0016","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1016\/0361-9230(89)90126-3","article-title":"Effect of 4-aminopyridine on axonal conduction-black in chronic spinal cord injury","volume":"22","author":"Blight","year":"1989","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.arrct.2021.100123_bib0017","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1038\/283570a0","article-title":"Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres","volume":"283","author":"Sherratt","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.arrct.2021.100123_bib0018","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0006-8993(86)90652-9","article-title":"Action potential characteristics of demyelinated rat sciatic nerve following application of 4-aminopyridine","volume":"363","author":"Targ","year":"1986","journal-title":"Brain Res"},{"key":"10.1016\/j.arrct.2021.100123_bib0019","doi-asserted-by":"crossref","first-page":"13448","DOI":"10.1212\/WNL.41.9.1344","article-title":"4Aminopyridine in multiple sclerosis: prolonged administration","volume":"41","author":"Stefoski","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.arrct.2021.100123_bib0020","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1089\/neu.1993.10.1","article-title":"4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients","volume":"10","author":"Hansebout","year":"1993","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.arrct.2021.100123_bib0021","doi-asserted-by":"crossref","first-page":"81721","DOI":"10.1212\/WNL.48.4.817","article-title":"Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis","volume":"48","author":"Schwid","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.arrct.2021.100123_bib0022","doi-asserted-by":"crossref","first-page":"71323","DOI":"10.1592\/phco.19.9.713.31540","article-title":"Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial","volume":"19","author":"Segal","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.arrct.2021.100123_bib0023","first-page":"3","article-title":"Improvement of motor, sensory, and functional status of post-Guillain-Barre syndrome with the use of 4-aminopyridine","volume":"2","author":"Meythaler","year":"2014","journal-title":"Int J Phys Med Rehabil"},{"issue":"Suppl","key":"10.1016\/j.arrct.2021.100123_bib0024","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1002\/ana.410360728","article-title":"The current status of studies of aminopyridines in patients with multiple sclerosis","volume":"36","author":"Bever","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.arrct.2021.100123_bib0025","unstructured":"American Spinal Injury Association. International standards for neurological classification of spinal cord injury. Available at: https:\/\/asia-spinalinjury.org\/isncsci-2019-revision-released\/. Accessed January 21, 2021."},{"key":"10.1016\/j.arrct.2021.100123_bib0026","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41393-019-0350-9","article-title":"ASIA and ISCoS International Standards Committee. The 2019 revision of the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)-What's new?","volume":"57","year":"2019","journal-title":"Spinal Cord"},{"key":"10.1016\/j.arrct.2021.100123_bib0027","doi-asserted-by":"crossref","first-page":"56673","DOI":"10.1016\/0003-9993(93)90153-2","article-title":"Relationship between impairment and physical disability as measure by the functional independence measure","volume":"74","author":"Heinemann","year":"1993","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.arrct.2021.100123_bib0028","doi-asserted-by":"crossref","first-page":"25860","DOI":"10.1016\/S0894-1130(98)80021-5","article-title":"Hand-grip dynamometry provides a valid indication of upper extremity strength impairment in home care patients","volume":"11","author":"Bohannon","year":"1998","journal-title":"J Hand Ther"},{"key":"10.1016\/j.arrct.2021.100123_bib0029","first-page":"311","article-title":"An objective and standardized test of hand function","volume":"50","author":"Jebsen","year":"1969","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.arrct.2021.100123_bib0030","first-page":"1649","article-title":"Extension of the Minnesota Rate of Manipulation Test","volume":"27","author":"Juregensen","year":"1943","journal-title":"J Appl Psychol"},{"key":"10.1016\/j.arrct.2021.100123_bib0031","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/10790268.2008.11753644","article-title":"Outcome measures for gait and ambulation in the spinal cord injury population","volume":"31","author":"Jackson","year":"2008","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.arrct.2021.100123_bib0032","first-page":"91923","article-title":"The 6minute walk: a new measure of exercise capacity in patients with chronic heart failure","volume":"132","author":"Guyatt","year":"1985","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.arrct.2021.100123_bib0033","first-page":"11117","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arrct.2021.100123_bib0034","doi-asserted-by":"crossref","first-page":"27799","DOI":"10.1016\/0304-3959(75)90044-5","article-title":"The McGill Pain Questionnaire: major properties and scoring methods","volume":"1","author":"Melzack","year":"1975","journal-title":"Pain"},{"key":"10.1016\/j.arrct.2021.100123_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/0304-3959(92)90076-N","article-title":"Evaluation of multi-dimensional pain scales","volume":"48","author":"Gracely","year":"1992","journal-title":"Pain"},{"key":"10.1016\/j.arrct.2021.100123_bib0036","doi-asserted-by":"crossref","first-page":"11726","DOI":"10.1016\/0304-3959(86)90228-9","article-title":"The measurement of pain intensity: a comparison of six methods","volume":"27","author":"Jensen","year":"1986","journal-title":"Pain"},{"key":"10.1016\/j.arrct.2021.100123_bib0037","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/014662167700100306","article-title":"One CES-D scale: a self report; depression scale for research in the general population","volume":"1","author":"Radloff","year":"1977","journal-title":"Appl Psychol Meas"},{"key":"10.1016\/j.arrct.2021.100123_bib0038","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1037\/0021-843X.95.3.282","article-title":"Etiologic factors in the onset of depressive symptoms in older adults","volume":"95","author":"Phifer","year":"1986","journal-title":"J Abnorm Psychol"},{"key":"10.1016\/j.arrct.2021.100123_bib0039","doi-asserted-by":"crossref","DOI":"10.1037\/0022-3514.54.6.1063","article-title":"Development and validation of brief measures of positive and negative affect: the PANAS scales","volume":"54","author":"Watson","year":"1988","journal-title":"J Pers Soc Psychol"},{"year":"1995","series-title":"SF-12: how to score the SF-12 physical and mental health summary scores","author":"Ware","key":"10.1016\/j.arrct.2021.100123_bib0040"},{"key":"10.1016\/j.arrct.2021.100123_bib0041","doi-asserted-by":"crossref","first-page":"12840","DOI":"10.1177\/0272989X9901900203","article-title":"The relationship between heath-state utilities and the SF-12 in a general population","volume":"19","author":"Lundberg","year":"1999","journal-title":"Med Decis Making"},{"key":"10.1016\/j.arrct.2021.100123_bib0042","doi-asserted-by":"crossref","first-page":"26571","DOI":"10.1212\/WNL.31.3.265","article-title":"Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission","volume":"31","author":"Murray","year":"1981","journal-title":"Neurology"},{"issue":"Suppl","key":"10.1016\/j.arrct.2021.100123_bib0043","first-page":"S136","article-title":"Guillain-Barre syndrome: clinical and therapeutic observations","volume":"27","author":"McKhann","year":"1990","journal-title":"Ann Neurol"},{"issue":"Suppl 8","key":"10.1016\/j.arrct.2021.100123_bib0044","first-page":"S2259","article-title":"Consensus criteria for the diagnosis of partial conduction block","volume":"22","author":"Olney","year":"1999","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.arrct.2021.100123_bib0045","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/mus.880120902","article-title":"AAEM case report #4: Guillain-Barre syndrome","volume":"12","author":"Albers","year":"1989","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.arrct.2021.100123_bib0046","doi-asserted-by":"crossref","first-page":"18692","DOI":"10.1002\/ana.410270215","article-title":"Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis","volume":"27","author":"Davis","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1016\/j.arrct.2021.100123_bib0047","doi-asserted-by":"crossref","first-page":"35362","DOI":"10.1016\/0022-510X(83)90145-4","article-title":"Effects of 4-aminopyridine in patients with multiple sclerosis","volume":"60","author":"Jones","year":"1983","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.arrct.2021.100123_bib0048","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.22240","article-title":"A phase 3 trial of extended release oral dalfampridine in multiple sclerosis","volume":"68","author":"Goodman","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.arrct.2021.100123_bib0049","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.15252\/emmm.201506035","article-title":"4-Aminopyridine promotes functional recovery and remyelination in acute peripheral nerve injury","volume":"8","author":"Tseng","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.arrct.2021.100123_bib0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.31532\/PhysMedRehabil.1.1.003","article-title":"Use of 4-aminopyridine for motor weakness due to Charcot-Marie-Tooth hereditary motor sensory neuropathy","volume":"1","author":"Meythaler","year":"2017","journal-title":"Phys Med Rehabil"},{"key":"10.1016\/j.arrct.2021.100123_bib0051","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/1673-5374.264471","article-title":"Transdermal delivery of 4-aminopyridine accelerates motor functional recovery and improves nerve morphology following sciatic nerve crush injury in mice","volume":"15","author":"Clark","year":"2020","journal-title":"Neural Regen Res"},{"issue":"Suppl 1","key":"10.1016\/j.arrct.2021.100123_bib0052","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/milmed\/usy399","article-title":"4-Aminopyridine as a single agent diagnostic and treatment for severe nerve crush injury","volume":"184","author":"Noble","year":"2019","journal-title":"Mil Med"}],"container-title":["Archives of Rehabilitation Research and Clinical Translation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590109521000276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590109521000276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:43:55Z","timestamp":1762911835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590109521000276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2590109521000276"],"URL":"https:\/\/doi.org\/10.1016\/j.arrct.2021.100123","relation":{},"ISSN":["2590-1095"],"issn-type":[{"type":"print","value":"2590-1095"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase IIB Randomized Trial on the Use of 4-Aminopyridine in Guillain-Barr\u00e9 Syndrome","name":"articletitle","label":"Article Title"},{"value":"Archives of Rehabilitation Research and Clinical Translation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arrct.2021.100123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of American Congress of Rehabilitation Medicine.","name":"copyright","label":"Copyright"}],"article-number":"100123"}}